GamaMabs licences AZ technology for new cancer therapy

10th October 2017 Uncategorised 0

French biotech GamaMabs Pharma has licensed technology owned by AstraZeneca’s MedImmune to research and produce a novel antibody-drug conjugate (ADC) to treat cancer.

More: GamaMabs licences AZ technology for new cancer therapy
Source: News